| Literature DB >> 36060643 |
Yuan Zhang1, Zhaoshang Zeng1, Fenghui Li1, Zhiyun Peng1, Han Xia2, Yunyi Zeng1, Haimin Chen1, Yingjing Wang1, Weining Xie3, Yanhua Zhang4, Zhongxiang Tang1.
Abstract
It remains a huge challenge for clinicians to diagnose Pneumocystis jirovecii pneumonia (PJP) by a conventional method, which leads to delay in diagnosing PJP, accounting for higher mortality in patients with rheumatoid arthritis (RA). A 69-year-old woman, who suffered from RA for years, developed acute respiratory failure. The computed tomography scan showed diffused effusion and ground glass opacity in both lungs, which could not be differentiated from interstitial pneumonia. Metagenomic next-generation sequencing (mNGS) revealed P. jirovecii in both serum and bronchoalveolar lavage fluid with reads per million (RPM) of 17 and 437, while other diagnostic tests did not detect any pathogenic microorganism. The results were verified by quantitative polymerase chain reaction (mtSSU region) against the same samples. The DNA RPM of P. jirovecii declined notably after treatment with trimethoprim/sulfamethoxazole. The patient was discharged without treatment and finally passed away. This case fully highlights the sensitivity of mNGS in early diagnosis of PJP, which is of great significance for prognosis and treatment. Nonetheless, the clinical application of mNGS is worth further standardization and normalization.Entities:
Keywords: Pneumocystis jirovecii pneumonia; case report; diagnosis; metagenomic next-generation sequencing; rheumatoid arthritis
Year: 2022 PMID: 36060643 PMCID: PMC9386609 DOI: 10.1515/biol-2022-0094
Source DB: PubMed Journal: Open Life Sci ISSN: 2391-5412 Impact factor: 1.311
The results of conventional methods and mNGS of this patient
| Time of sample collection | Time of test report | Diagnostic methods | Results |
|---|---|---|---|
| Dec. 26 | Dec. 26 | PCR of COVID-19 | Negative |
| Dec. 29 | Sputum/urine/blood cultures | Negative | |
| Dec. 28 | Dec. 30 | BALF culture | Negative |
| Dec. 29 | BALF smear | Gram-negative | |
| Dec. 29 | BALF GeneXpert MTB | Negative | |
| Dec. 29 | BALF GM test | Negative | |
| Dec. 29 | BALF mNGS |
| |
| Dec. 29 | Blood mNGS |
| |
| Jan. 3 | Bone marrow biopsy | Negative | |
| Dec. 29 | Dec. 30 | qPCR of | Positive |
| Jan. 3 | Jan. 4 | BALF mNGS |
|
| Jan. 4 | Blood mNGS |
| |
| Jan. 12 | Jan. 13 | BALF mNGS |
|
| Jan. 13 | Blood mNGS |
| |
| Jan. 18 | Jan. 19 | BALF mNGS |
|
| Jan. 19 | Blood mNGS |
|
Figure 1The chest images of this patient. The CT scan showed diffused effusion and GGO in both lungs.
Figure 2The bone marrow biopsy result of the patient. Hemophagocyte was detected in bone marrow smear.
Figure 3The results of mNGS and qPCR: (a) coverage and reads number of detected P. jirovecii by BALF-mNGS on December 28th, (b) coverage and reads number of detected P. jirovecii by blood-mNGS on December 28th, and (c) qPCR results of mtSSU region of P. jirovecii, four out of the eight samples were positive.
Figure 4Change of P. jirovecii DNA reads in BALF and serum. During the 21-day treatment, the DNA reads of P. jirovecii by mNGS using both serum and BALF disclosed a dramatic increase since the medication of TMP/SMX, then declined gradually.